Lynkuet shows promise for cancer-related menopause symptoms

Sudden menopause impacts cancer treatment adherence

Cancer treatment can cause an abrupt onset of menopause symptoms, which some patients describe as a sudden plummet with no time for adjustment. Hot flashes are a common and bothersome side effect of endocrine therapies such as tamoxifen or aromatase inhibitors, particularly in premenopausal women.

Lambertini, who is also an associate professor at the University of Genoa, warns that this discontinuation can lead to suboptimal clinical outcomes.

Initial management strategies for endocrine therapy side effects

Non-pharmacological strategies for managing hot flashes include yoga, acupuncture, physical exercise, and cognitive behavioural therapy. These methods are recommended as the initial approach for patients experiencing side effects such as hot flashes, fatigue, and joint pain from endocrine therapy.

While low-dose antidepressants are a pharmacological option, Dr. Lambertini notes they are often difficult to prescribe. Lambertini notes they are often difficult to prescribe. He says patients are frequently reluctant to take them because of additional side effects.

Lynkuet mechanism and CDK4/6 inhibitor considerations

The drug is a non-hormonal medication that functions by blocking the NK1 and NK3 receptors in the brain, which are involved in body temperature regulation.

There is no specific data regarding the use of elinzanetant with CDK4/6 inhibitors. Lambertini states there is no particular concern with abemaciclib (Verzenio), but there is a potential concern with ribociclib (Kisqali) due to the risk of liver toxicity.

Professional certification in menopause care

Medical oncologist Laila Agrawal obtained the 2026 Menopause Society Certified Practitioner (MSCP) Badge from The Menopause Society.

Holding the MSCP Badge can result in higher salaries, job promotions, and increased patient referrals for practitioners.

Addressing the underserved needs of cancer survivors

Medical professionals, including breast cancer survivors, have identified cancer survivors as an underserved group regarding the management of menopause symptoms. One patient diagnosed with lymphoma reported that her symptoms, including cortisol spikes and insulin resistance, were previously dismissed as anxiety or perimenopause.

A woman who underwent a double mastectomy for ductal carcinoma in situ breast cancer reported experiencing survivor guilt following her recovery. Reports state that women who have had cancer should have a choice regarding the prescription of hormone treatments.

Future research on treatment adherence

The OASIS-4 trial did not evaluate whether improved management of hot flashes leads to better patient adherence to endocrine therapy.

Future real-world studies on the safety and effectiveness of elinzanetant are expected to investigate adherence rates, which are considered a critical issue in the prescription of adjuvant endocrine therapy.

Historical context of elinzanetant trials

A phase 3 trial of elinzanetant was published in the New England Journal of Medicine one year prior to the November 2026 report.